Indefinite Delivery Contract 75N93022D00003
Award Date
12/1/21
Last Date to Order
11/30/28
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Duke University
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Pricing Type
Cost Plus Fixed Fee
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to support preclinical and translational vaccine development services for HIV vaccines and other candidate agents. The total potential value of the contracts is $364,553,934 over a seven-year period of performance from December 2021 through November 2028. The contracts will provide a broad range of capabilities required for preclinical and...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts totaling approximately $364.5 million to support preclinical and translational vaccine development services. Task areas include product storage and shipping, safety and immunogenicity studies, feasibility assessments, analytical development, process development, cGMP manufacturing, stability testing, fill-finish, and scientific support. Task...
This indefinite delivery contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to support preclinical and translational vaccine development for HIV and other candidate agents. The multiple award IDV has a potential value of $364,553,934 over a seven year ordering period from December 2021 to November 2028. The contract aims to procure a broad range of capabilities for preclinical and translational development support. This includes...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. The total potential value of the IDV is $107,274,471 over seven years ending October 2027. Task orders have been issued under several areas. Lovelace Biomedical Research Institute received a $18,397 order to develop...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts with a total potential value of $364,553,934 to support preclinical and translational vaccine development services. Task areas under the contracts include product storage and shipping, safety and immunogenicity studies, feasibility assessments, analytical development, process development, cGMP manufacturing, stability testing, fill-finish, and...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, has awarded a $107,274,471 Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Southern Research Institute, a non-profit research organization, to provide preclinical development support for candidate products and drug development activities related to HIV therapeutics. The contract does not have a set-aside designation and has a period of...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded this $107,274,471 Indefinite Delivery/Indefinite Quantity (IDIQ) contract to the University of North Carolina at Chapel Hill (UNC-CH) to provide preclinical development support for candidate products and drug development activities related to infectious diseases like HIV, hepatitis, and tuberculosis. The contract encompasses a wide range of services including in...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. Valued at up to $107 million over seven years, the contracts authorize task orders across seven areas including in vitro testing, synthesis of therapeutic agents, small animal models, formulation development,...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded an Indefinite Delivery Contract (IDC) to the International AIDS Vaccine Initiative (IAVI), a global non-profit organization, to provide a range of research, development, manufacturing, and advocacy services to advance the creation and delivery of vaccines and antibodies for infectious diseases. The contract, valued at up to $98.6 million, has a period of performance...
The National Institute of Allergy and Infectious Diseases has awarded an indefinite delivery contract with a potential value of $107,274,471 to multiple prime contractors to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. Task orders will be issued under seven task areas, including in vitro testing, synthesis of therapeutic agents, small animal...